Fate’s Phase I NK Cell Therapy Sparks Optimism, But Longer Follow-Up Needed

 
• By Alaric DeArment
  
3d illustration of T cells or cancer cells
Fate Therapeutics presented early data at ASCO on its NK cell therapy program • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from ASCO

More from Conferences